ArticleNature communications2021
Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 77 citations in OpenAlex.
- Modeling human tumor evolution in mice.STAR protocols · 2026Review
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- CDK9 inhibition sensitizes intrinsically resistantActa pharmaceutica Sinica. B · 2026Article
- Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.Nature genetics · 2026Article
- Multi-Transcriptomic Analysis Reveals That EREG-Driven TME Crosstalk Defines Anti-EGFR Response in Colorectal Cancer.Cancer medicine · 2026Article
- Article
- MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.Nature · 2026Article
- Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.Cancer research communications · 2026Article
- Key genes and pathway differences between serrated polyps and conventional adenomas: insights from multi-omics.Translational cancer research · 2026Article
- Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.NPJ precision oncology · 2026Article
- Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation.Nature genetics · 2026Article
- Article
- Evaluating the anti-gut dysbiotic potential of bioactive primary metabolites derivatives fromFrontiers in nutrition · 2026Article
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- Fosl1 is a transcriptional effector ofiScience · 2025Article
- Defining the mucosal ecosystem: epithelial-mesenchymal interdependence in gastrointestinal health and disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1 -mutated oral squamous cell carcinoma.Chinese medical journal · 2025Article
- Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications.Cancer science · 2025Article
- Model systems to study tumor-microbiome interactions in early-onset colorectal cancer.EMBO molecular medicine · 2025Review
- The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 18 institutions in 5 countries.
Joshua D G LeachCancer Research UK Beatson Institute, Glasgow, UK.
Nikola VlahovCancer Research UK Beatson Institute, Glasgow, UK.
Petros TsantoulisDepartment of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-3613-6682
Rachel A RidgwayCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-0198-8244
Dustin J FlanaganCancer Research UK Beatson Institute, Glasgow, UK.
Kathryn GilroyCancer Research UK Beatson Institute, Glasgow, UK.
Nathalie SphyrisCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-1860-1958
Ester G VázquezGastrointestinal Stem Cell Biology Lab, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
David F VincentCancer Research UK Beatson Institute, Glasgow, UK.
William J FallerDivision of Oncogenomics, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0738-2254
Michael C HodderCancer Research UK Beatson Institute, Glasgow, UK.
Alexander RavenCancer Research UK Beatson Institute, Glasgow, UK.
Sigrid FeyCancer Research UK Beatson Institute, Glasgow, UK.
Arafath K NajumudeenCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-3764-5721
Douglas StrathdeeCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-2959-4327
Colin NixonCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-8085-2160
Mark HughesCancer Research UK Beatson Institute, Glasgow, UK.
William ClarkCancer Research UK Beatson Institute, Glasgow, UK.
Robin ShawCancer Research UK Beatson Institute, Glasgow, UK.
S:CORT consortium
Sander R van HooffLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
David J HuelsLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
Jan Paul MedemaLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
Simon T BarryBioscience, Early Oncology, AstraZeneca, Cambridge, UK.
Margaret C FrameCancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-5882-1942
Asier Unciti-BrocetaCancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0003-1029-2855
Simon J LeedhamGastrointestinal Stem Cell Biology Lab, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Gareth J InmanCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-6264-4253
Rene JackstadtCancer Research UK Beatson Institute, Glasgow, UK.
Barry J ThompsonEMBL Australia, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ORCID http://orcid.org/0000-0002-0103-040X
Andrew D CampbellCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-3930-1276
Sabine TejparMolecular Digestive Oncology, Department of Oncology, University of Leuven, Leuven, Belgium.
Owen J SansomCancer Research UK Beatson Institute, Glasgow, UK. o.sansom@beatson.gla.ac.uk.ORCID http://orcid.org/0000-0001-9540-3010
Cancer Research UK Scotland Institute · GBUniversity of Oxford · GBAmsterdam UMC Location University of Amsterdam · NLCentre for Human Genetics · GBQueen's University Belfast · GBEdinburgh Cancer Research · GBUniversity College London · GBAstraZeneca (United Kingdom) · GBAustralian National University · AUBeatson West of Scotland Cancer Centre · GBKU Leuven · BEThe Netherlands Cancer Institute · NLUniversity of Bern · CHUniversity of Birmingham · GBUniversity of Edinburgh · GBUniversity of Geneva · CHUniversity of Leeds · GBWellcome Sanger Institute · GB
Funding
Cancer Research UK 21139Cancer Research UK 27144Cancer Research UK 29802Cancer Research UK A12481Cancer Research UK A17196Cancer Research UK A21139Cancer Research UK A29055Cancer Research UK A29802Cancer Research UK C7932/A26825Medical Research Council MC_UU_00004/01Medical Research Council MC_UU_12023/20Medical Research Council MR/M016587/1Medical Research Council MR/N021800/1Wellcome Trust 206314/Z/17/Z
Abstract
Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1
Indexed as
Signal TransductionAdaptor Proteins, Signal TransducingAnimalsCarcinogenesisCell DifferentiationCell SurvivalColonColonic NeoplasmsEpithelial CellsFetusInflammationKaplan-Meier EstimateMAP Kinase Signaling SystemMiceMice, Inbred C57BLMutationAdaptor Proteins, Signal TransducingProto-Oncogene Proteins B-rafReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ITgfbr1 protein, mouseTranscription FactorsTransforming Growth Factor betaWnt ProteinsYAP1 protein, humanYAP-Signaling Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.